EA201491268A1 - Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию - Google Patents
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связываниюInfo
- Publication number
- EA201491268A1 EA201491268A1 EA201491268A EA201491268A EA201491268A1 EA 201491268 A1 EA201491268 A1 EA 201491268A1 EA 201491268 A EA201491268 A EA 201491268A EA 201491268 A EA201491268 A EA 201491268A EA 201491268 A1 EA201491268 A1 EA 201491268A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- interaction
- bcl2
- partners
- linkage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к соединениям формулы (I), в которой R, R, Rи Rопределены в описании изобретения. Соединения формулы (I) способны нарушать BCL-2 взаимодействия с белками, содержащими ВН3 домен. Нарушение данного взаимодействия может восстанавливать антиапоптозную функцию BCL-2 в раковых клетках и опухолевой ткани, экспрессирующих BCL-2. Кроме того, изобретение относится к способу получения соединений, фармацевтических препаратов, содержащих данные соединения, и способам применения данных соединений в лечении раковых заболеваний.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579731P | 2011-12-23 | 2011-12-23 | |
PCT/US2012/069181 WO2013096049A1 (en) | 2011-12-23 | 2012-12-12 | Compounds for inhibiting the interaction of bcl2 with binding partners |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201491268A1 true EA201491268A1 (ru) | 2014-11-28 |
Family
ID=47429049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491268A EA201491268A1 (ru) | 2011-12-23 | 2012-12-12 | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию |
Country Status (11)
Country | Link |
---|---|
US (1) | US9126980B2 (ru) |
EP (1) | EP2794588A1 (ru) |
JP (1) | JP2015503515A (ru) |
KR (1) | KR20140107573A (ru) |
CN (1) | CN104125955A (ru) |
AU (1) | AU2012355613A1 (ru) |
BR (1) | BR112014015274A2 (ru) |
CA (1) | CA2859862A1 (ru) |
EA (1) | EA201491268A1 (ru) |
MX (1) | MX2014007729A (ru) |
WO (1) | WO2013096049A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126979B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
FR3008979B1 (fr) | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3008976A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
FR3008978A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
CA3073656C (en) | 2017-09-22 | 2024-03-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
SG11202004143XA (en) | 2017-11-06 | 2020-06-29 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
CN111542523B (zh) | 2017-11-24 | 2024-03-29 | 朱比连特埃皮斯科瑞有限责任公司 | 作为prmt5抑制剂的杂环化合物 |
CA3093527A1 (en) | 2018-03-13 | 2019-09-19 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
CA3098348A1 (en) | 2018-04-29 | 2019-11-07 | Beigene, Ltd. | Bcl-2 inhibitors |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
TW225528B (ru) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
DK0666868T4 (da) | 1992-10-28 | 2006-09-18 | Genentech Inc | Anvendelse af anti-VEGF-antistoffer til behandling af cancer |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US6140332A (en) | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ATE213730T1 (de) | 1996-04-12 | 2002-03-15 | Warner Lambert Co | Umkehrbare inhibitoren von tyrosin kinasen |
DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
WO1998010121A1 (en) | 1996-09-06 | 1998-03-12 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
CA2322157C (en) | 1998-02-25 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
BR9912938B1 (pt) | 1998-08-11 | 2011-06-28 | derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos. | |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (ru) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ |
WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
CA2355976C (en) | 1998-12-22 | 2012-07-17 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
CN1221262C (zh) | 1999-03-30 | 2005-10-05 | 诺瓦提斯公司 | 治疗炎性疾病的酞嗪衍生物 |
AU2001284942A1 (en) | 2000-08-16 | 2002-02-25 | Georgetown University Medical Center | Small molecule inhibitors targeted at bcl-2 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
AU2002305769B2 (en) | 2001-05-30 | 2007-07-19 | Georgetown University | Small molecule antagonists of Bcl2 family proteins |
US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US8557812B2 (en) * | 2004-08-20 | 2013-10-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
EP2094672B1 (en) | 2006-11-15 | 2013-05-29 | Genentech, Inc. | Arylsulfonamide compounds |
WO2011029842A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
US9126979B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EA201491265A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
CN104136428A (zh) | 2011-12-23 | 2014-11-05 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
-
2012
- 2012-12-12 KR KR1020147020518A patent/KR20140107573A/ko not_active Application Discontinuation
- 2012-12-12 BR BR112014015274A patent/BR112014015274A2/pt not_active Application Discontinuation
- 2012-12-12 AU AU2012355613A patent/AU2012355613A1/en not_active Abandoned
- 2012-12-12 WO PCT/US2012/069181 patent/WO2013096049A1/en active Application Filing
- 2012-12-12 CN CN201280070506.9A patent/CN104125955A/zh active Pending
- 2012-12-12 CA CA2859862A patent/CA2859862A1/en not_active Abandoned
- 2012-12-12 EA EA201491268A patent/EA201491268A1/ru unknown
- 2012-12-12 JP JP2014549133A patent/JP2015503515A/ja active Pending
- 2012-12-12 MX MX2014007729A patent/MX2014007729A/es unknown
- 2012-12-12 US US14/366,858 patent/US9126980B2/en not_active Expired - Fee Related
- 2012-12-12 EP EP12805893.0A patent/EP2794588A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MX2014007729A (es) | 2015-01-12 |
JP2015503515A (ja) | 2015-02-02 |
CN104125955A (zh) | 2014-10-29 |
BR112014015274A8 (pt) | 2017-06-13 |
KR20140107573A (ko) | 2014-09-04 |
CA2859862A1 (en) | 2013-06-27 |
EP2794588A1 (en) | 2014-10-29 |
WO2013096049A1 (en) | 2013-06-27 |
BR112014015274A2 (pt) | 2017-06-13 |
US20150080428A1 (en) | 2015-03-19 |
AU2012355613A1 (en) | 2014-07-17 |
US9126980B2 (en) | 2015-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201491260A1 (ru) | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию | |
EA201491268A1 (ru) | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию | |
EA201491265A1 (ru) | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию | |
EA201491264A1 (ru) | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию | |
CY1122165T1 (el) | Αντισωματα anti-cd38 | |
CY1117986T1 (el) | Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου | |
EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
EA201491259A1 (ru) | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания | |
EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
EA201500394A1 (ru) | Ингибиторы деметилаз гистонов | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
EP4338754A3 (en) | Antigen binding proteins | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
MX344530B (es) | Compuestos de benceno substituido. | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
EA201890754A1 (ru) | Соединения и способы их применения | |
TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
NZ704269A (en) | Rspo3 binding agents and uses thereof | |
EA201201676A1 (ru) | Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы | |
EA201690237A1 (ru) | Позитивные аллостерические модуляторы никотинового рецептора ацетилхолина | |
WO2012088491A3 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | |
TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists | |
UA110969C2 (uk) | Арил- або гетероарилзаміщені бензольні сполуки та фармацевтична композиція на їх основі |